Shorted
Clarity Pharmaceuticals logo
CU6
Pharmaceuticals, Biotechnology & Life Sciences

Clarity Pharmaceuticals

Short interest
9.72%
+1.34 pp 30d
as of 12 Oct 2026
Reported shorts
36.3M
Shares on issue
373.081M

Clarity Pharmaceuticals (CU6) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Positive
5 Oct

State Street Corporation Declares Initial 5.25% Stake in Clarity Pharmaceuticals (ASX:CU6)

On 1 October 2026, State Street Corporation and its designated subsidiaries became a substantial shareholder in Clarity Pharmaceuticals Ltd (ASX:CU6), holding a relevant interest in 19,603,851 ordinary shares, which accounts for 5.25% of the company’s voting power. Key Highlights State Street Corporation and its named subsidiaries acquired substantial holding status in Clarity Pharmaceuticals on 1 October 2026. The group holds 19,603,851 ordinary shares, representing 5.25% of the voting rig...

Continue reading
Kalkine
Neutral
21 Sept

Clarity Pharmaceuticals Announces Annual General Meeting Date for 25 November 2026

Clarity Pharmaceuticals (ASX:CU6), a clinical-stage radiopharmaceutical firm dedicated to advancing next-generation cancer therapies, has confirmed its Annual General Meeting will be held on 25 November 2026, complying with ASX Listing Rule 3.13.1. Key Points Annual General Meeting set for 25 November 2026 Announcement made under ASX Listing Rule 3.13.1 Deadline for director nominations is 7 October 2026 Separate Notice of Meeting to be issued to shareholders and posted on the ASX Company Ann...

Continue reading
Kalkine
Neutral
5 Aug

State Street Corporation Declares 5.02% Stake in Clarity Pharmaceuticals (ASX:CU6)

Clarity Pharmaceuticals Ltd (ASX:CU6) has been notified of an initial substantial holding by State Street Corporation and its subsidiaries, revealing a relevant interest in 18,717,504 ordinary shares, which represent 5.02% of voting power. This substantial holder status took effect on 3 August 2026. Key Points State Street Corporation and its designated subsidiaries became substantial holders in Clarity Pharmaceuticals as of 3 August 2026. The combined relevant interest totals 18,717,504 ordi...

Continue reading
Kalkine
Neutral
5 Aug

Clarity Pharmaceuticals Grants 9.37 Million Unquoted Options Under Employee Incentive Plan

Clarity Pharmaceuticals Ltd (ASX:CU6) announced the issuance of 9,374,557 unquoted options as part of its employee incentive scheme. These securities were issued on 3 August 2026, with the official notification submitted on 5 August 2026. Key Points 9,374,557 unquoted options (ASX code: CU6AAM) issued on 3 August 2026 under the employee incentive scheme Key management personnel David Green was allocated 305,823 of these options Options vest in three tranches: 25% on 1 July 2027, 25% on 1 July...

Continue reading
Kalkine
Neutral
4 Aug

Could Clarity Pharmaceuticals (ASX:CU6) Be Australia's Next Small-Cap Healthcare Surprise?

Highlights Clarity Pharmaceuticals, PolyNovo and Wagners Holding are attracting attention for their operational progress and financial quality. Healthcare innovation and specialised industrial capabilities continue creating opportunities across Australia's smaller listed companies. Balance-sheet strength, execution and commercial expansion remain the key themes shaping investor interest. Australia's reporting season has produced mixed market sentiment as global geopolitical developments and ec...

Continue reading
Kalkine
Neutral
8 July

Is Clarity Pharmaceuticals (ASX:CU6) Redefining Cancer Treatment Through Its Copper Theranostics Platform?

Highlights Clarity Pharmaceuticals continues advancing its proprietary Targeted Copper Theranostics platform across multiple oncology programs. Phase III studies and additional clinical data remain key milestones for the clinical-stage biotechnology company. The radiopharmaceutical developer continues expanding its presence within the ASX Healthcare Stocks sector alongside the [ASX 200] healthcare landscape. Clarity Pharmaceuticals Ltd (ASX:CU6) continues ...

Continue reading
Kalkine
Positive
29 June

Clarity Pharmaceuticals (ASX:CU6) Advances Prostate Cancer Research, Shares Gain Attention

Highlights Clarity Pharmaceuticals attracted market attention after announcing multiple research presentations at a leading European nuclear medicine conference. New clinical data will showcase the company's radiopharmaceutical technology for prostate cancer diagnosis and treatment. Patient case studies highlighted the potential clinical applications of Clarity's imaging platform. Clarity Pharmaceuticals Ltd (ASX:CU6) moved into focus after announcing that new...

Continue reading